RecruitingNCT05242744

FTT PET/CT in Metastatic Prostate Cancer

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Patients With Metastatic Prostate Cancer

Sponsor

Abramson Cancer Center at Penn Medicine

Enrollment

30 participants

Start Date

Mar 1, 2023

Study Type

OBSERVATIONAL

Conditions

Prostate Cancer Metastatic

Summary

Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer. Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment. Tissue from a clinical or research biopsy will be compared to imaging measures, if available.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This imaging study uses a specialized PET/CT scan with a tracer called FTT (which sticks to cancer cells with certain DNA repair mutations) to better identify which patients with metastatic prostate cancer are most likely to benefit from PARP inhibitor therapy or other targeted treatments. **You may be eligible if...** - You are 18 or older with confirmed metastatic prostate cancer - You have at least one tumor visible on standard imaging - Your doctor is considering changing or starting treatment (such as PARP inhibitors or hormone therapy) **You may NOT be eligible if...** - You are unable to tolerate the imaging procedure - Your doctor determines another medical condition makes participation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[18F]FluorThanatrace

Investigational radiopharmaceutical used with Positron Emission Tomography (PET/CT) imaging that may provide a non-invasive measurement of PARP-1 expression